文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

用于益生菌生物膜和后生元口服共递送的微流控衍生蒙脱石复合微粒

Microfluidic-derived montmorillonite composite microparticles for oral codelivery of probiotic biofilm and postbiotics.

作者信息

Fang Zhonglin, Yang Xinyuan, Shang Luoran

机构信息

Shanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, and the Shanghai Key Laboratory of Medical Epigenetics, the International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.

出版信息

Sci Adv. 2025 Mar 21;11(12):eadt2131. doi: 10.1126/sciadv.adt2131. Epub 2025 Mar 19.


DOI:10.1126/sciadv.adt2131
PMID:40106563
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11922048/
Abstract

Oral delivery of probiotics has shown promising effects in modulating the gut microbiota and treating ulcerative colitis (UC). However, the therapeutic efficacy is restricted by gastrointestinal assaults, poor mucosal adhesion, and single therapeutic modality. Here, we developed acid-resistant, gut-environment-responsive composite microparticles based on microfluidic electrospray for the oral codelivery of probiotic [ (LA)] biofilm and postbiotics (indole-3-propionic acid). Montmorillonite was selected for supporting biofilm formation due to its cation-exchange capability and clearly defined biosafety. The montmorillonite-LA biofilm was effectively protected by the microparticles and markedly improved the intestinal retention. Upon oral administration, the composite microparticles notably alleviated colitis in mice, including reducing the inflammatory response, improving intestinal barrier function, and modulating the gut microbiota. Consequently, the composite microparticles show high potential for enhancing probiotic delivery efficacy and present a promising strategy for UC treatment.

摘要

口服益生菌已显示出在调节肠道微生物群和治疗溃疡性结肠炎(UC)方面的良好效果。然而,其治疗效果受到胃肠道攻击、黏膜黏附性差以及单一治疗方式的限制。在此,我们基于微流控电喷雾技术开发了耐酸、肠道环境响应性复合微粒,用于口服共递送益生菌[(LA)]生物膜和后生元(吲哚 - 3 - 丙酸)。由于蒙脱石具有阳离子交换能力且生物安全性明确,因此选择其来支持生物膜形成。蒙脱石 - LA生物膜受到微粒的有效保护,并显著提高了在肠道中的滞留时间。口服给药后,复合微粒显著减轻了小鼠的结肠炎,包括减轻炎症反应、改善肠道屏障功能以及调节肠道微生物群。因此,复合微粒在提高益生菌递送效果方面具有很高的潜力,并为UC治疗提供了一种有前景的策略。

相似文献

[1]
Microfluidic-derived montmorillonite composite microparticles for oral codelivery of probiotic biofilm and postbiotics.

Sci Adv. 2025-3-21

[2]
Microfluidic-based multifunctional microspheres for enhanced oral co-delivery of probiotics and postbiotics.

Biomaterials. 2024-7

[3]
Probiotics (Lactobacillus plantarum HNU082) Supplementation Relieves Ulcerative Colitis by Affecting Intestinal Barrier Functions, Immunity-Related Gene Expression, Gut Microbiota, and Metabolic Pathways in Mice.

Microbiol Spectr. 2022-12-21

[4]
Dihydromyricetin/montmorillonite intercalation compounds ameliorates DSS-induced colitis: Role of intestinal epithelial barrier, NLRP3 inflammasome pathway and gut microbiota.

Int J Pharm. 2025-2-10

[5]
protects against infection by regulating the autophagy of macrophages and maintaining gut microbiota homeostasis in C57BL/6 mice.

mSystems. 2024-7-23

[6]
Evodiamine has therapeutic efficacy in ulcerative colitis by increasing Lactobacillus acidophilus levels and acetate production.

Pharmacol Res. 2020-9

[7]
016 Alleviates Mice Colitis by Modulating Oxidative Stress, Gut Microbiota, and Microbial Metabolism.

Nutrients. 2025-1-26

[8]
Lactobacillus acidophilus and Clostridium butyricum ameliorate colitis in murine by strengthening the gut barrier function and decreasing inflammatory factors.

Benef Microbes. 2018-7-17

[9]
Therapeutic potential of Lacticaseibacillus rhamnosus grx10 and its derived postbiotic through gut microbiota and MAPK/MLCK/MLC pathway-mediated intestinal barrier repairment in ulcerative colitis.

J Food Sci. 2024-12

[10]
Orally-administrable supramolecular probiotic capsules enable cooperative colon-targeted inflammation inhibition for ameliorating ulcerative colitis.

Acta Biomater. 2025-3-1

引用本文的文献

[1]
Using Postbiotics from Functional Foods for Managing Colorectal Cancer: Mechanisms, Sources, Therapeutic Potential, and Clinical Perspectives.

Microorganisms. 2025-6-9

本文引用的文献

[1]
Armored probiotics for oral delivery.

Smart Med. 2023-7-20

[2]
Oral microsphere formulation of M2 macrophage-mimetic Janus nanomotor for targeted therapy of ulcerative colitis.

Sci Adv. 2024-6-28

[3]
Reinforcement of the intestinal mucosal barrier via mucus-penetrating PEGylated bacteria.

Nat Biomed Eng. 2024-7

[4]
Microfluidic-based multifunctional microspheres for enhanced oral co-delivery of probiotics and postbiotics.

Biomaterials. 2024-7

[5]
Microfluidics-Derived Microparticles with Prebiotics and Probiotics for Enhanced In Situ Colonization and Immunoregulation of Colitis.

Nano Lett. 2024-1-31

[6]
generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8 T cells.

Gut. 2023-11

[7]
Polydopamine-cladded montmorillonite micro-sheets as therapeutic platform repair the gut mucosal barrier of murine colitis through inhibiting oxidative stress.

Mater Today Bio. 2023-5-3

[8]
Rosmarinic Acid Restores Colonic Mucus Secretion in Colitis Mice by Regulating Gut Microbiota-Derived Metabolites and the Activation of Inflammasomes.

J Agric Food Chem. 2023-3-22

[9]
Prodrug Integrated Envelope on Probiotics to Enhance Target Therapy for Ulcerative Colitis.

Adv Sci (Weinh). 2023-2

[10]
Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery.

Nat Commun. 2022-6-14

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索